Please assess the completion status of the following clinical trial:

Trial Title: Bexagliflozin Efficacy and Safety Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a diagnosis of T2DM~* Subjects who have had a stable treatment regimen for T2DM for the past 3 months~* Subjects who present with at least one of the following 3 histories:~Group 1: A history of atherosclerotic vascular disease Group 2: A history of heart failure Group 3: Age ≥ 55 years with diabetes for ≥ 10 years, uncontrolled hypertension, currently smoking, reduced kidney function, or cholesterol problems~Exclusion Criteria:~* Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young~* History of genitourinary tract infections~* Evidence of abnormal liver function~* History of MI, stroke or hospitalization for heart failure in the past 3 months~* Prior kidney transplant or evidence of kidney problems~* Prior or planned pace maker implantation~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bexagliflozin tablets, 20 mg (Type: ACTIVE_COMPARATOR): Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.
- Placebo tablets (Type: PLACEBO_COMPARATOR): Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).